Mucous membrane and bronchial smooth muscle

The mucous membrane and bronchial smooth muscle are integral structural components of the tracheobronchial tree that maintain airway patency and defense. The respiratory mucous membrane consists of a ciliated epithelium and goblet cells that facilitate mucociliary clearance and provide an immune barrier against inhaled pathogens (StatPearls, 2023). Bronchial smooth muscle surrounds the airways and regulates airflow resistance through contraction and relaxation in response to various autonomic and local stimuli (NIH, 2022). In chronic respiratory diseases like asthma and COPD, these tissues undergo significant remodeling, including smooth muscle hypertrophy and mucosal inflammation, which lead to persistent airway narrowing (PubMed, 2021). Pharmacological treatments for these conditions are designed to act on specific receptors located within these tissues, such as beta-2 adrenergic receptors to induce bronchodilation or muscarinic receptors to reduce secretions. Because these tissues are the primary site of pathology in obstructive lung disease, they are the central focus of aerosolized drug delivery and clinical monitoring via pulmonary function tests. Consequently, while they represent anatomical sites rather than a single molecular target, they are the physiological foundation for respiratory pharmacology.

Other names

Respiratory mucosaAirway smooth muscleBronchial mucosaTracheobronchial smooth muscle

Drugs acting on these tissues function by modulating autonomic receptors or inflammatory pathways; for example, beta-2 adrenergic agonists increase intracellular cAMP to relax smooth muscle, while muscarinic antagonists block acetylcholine-induced contraction and mucus hypersecretion (StatPearls, 2023; PubMed, 2022).